A daily injection of a drug initially developed for diabetes may reverse Alzheimer’s, early research suggests.
Scientists at Lancaster University found the treatment - called a triple receptor agonist - significantly improved memory and reduced toxins in the brain when tested on mice.
Experts last night said the drug has ‘clear promise’ to eventually become the first treatment to tackle Alzheimer’s.
Scientists at Lancaster University found the treatment – called a triple receptor agonist – significantly improved memory and reduced toxins in the brain when tested on mice
The drug is some way off becoming available to patients, having only been tested on animals so far, but if it shows the same results in humans it could in time solve the desperate need for an effective treatment for the booming number of people suffering from Alzheimer’s. Dr Doug Brown, director of research at the Alzheimer’s Society which funded the study, said: ‘With no new treatments in nearly 15 years, we need to find new ways of tackling Alzheimer’s.
‘It’s imperative that we explore whether drugs developed to treat other conditions can benefit people with Alzheimer’s and other forms of dementia. This approach to research could make it much quicker to get promising new drugs to the people who need them. Further development of this work is crucial.’
The treatment contains three hormones which work in a triple attack against different causes of Alzheimer’s.
The three hormones are already separately used to treat type two diabetes, because they improve the body’s sensitivity to insulin.
But researchers found in recent trials they are more effective as a